Journal Article
. 1985 Oct; 135(4):2865-75.

In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2

M T Lotze  Y L Matory  S E Ettinghausen  A A Rayner  S O Sharrow  C A Seipp  M C Custer  S A Rosenberg  
  • PMID: 2993418
  •     132 citations


Purified recombinant human interleukin 2 (RIL 2) derived from E. coli containing the inserted gene encoding for IL 2 was administered to 20 patients with a variety of malignancies. Toxicity was dose related and included fever, chills, malaise, arthralgias, myalgias, and unexpectedly, weight gain related to marked fluid retention. All patients receiving more than 10(5) U/kg total cumulative dose developed evidence of fluid retention, and all patients requiring discontinuance of RIL 2 (11/20) received total doses of between 2.54 X 10(5) U/kg to 15.4 X 10(5) U/kg. The limiting dose with this preparation was 3000 U/kg/hr by continuous administration or 10(6) U/kg by bolus administration. IL 2 was rapidly cleared from the plasma, with a half life of 6.9 min, and a later delayed clearance was consistent with a two-compartment model, with slower release from the extravascular space back into the plasma compartment. A marked change in lymphoid cells in the periphery was noted with an early depletion of all lymphoid cells, followed by an expansion of such cells with continuous IL 2 administration. A twofold to 16-fold expansion of total lymphoid cells in the peripheral blood could be demonstrated. TAC+ cells representing up to 25% of the circulating peripheral blood mononuclear cells could be demonstrated with 3 wk of continuous RIL 2 administration. Interferon-gamma levels increased in patients treated with IL 2. Precursors of lymphokine-activated killer cells generated under standard conditions were depleted within 2 to 3 min after IL 2 administration, but repopulated the peripheral blood after 7 to 10 days of continuous IL 2 administration. No tumor regression was seen in any of the cancer patients treated with IL 2 alone.

Other Links

Induction of soluble tumour necrosis factor receptors during treatment with interleukin-2.
D W Miles, D Aderka, +2 authors, F R Balkwill.
Br J Cancer, 1992 Dec 01; 66(6). PMID: 1333789    Free PMC article.
A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects.
L T Vlasveld, E M Rankin, +6 authors, C J Melief.
Br J Cancer, 1992 May 01; 65(5). PMID: 1586602    Free PMC article.
Clinical and immunological effects of single bolus administration of recombinant interleukin-2 in cattle.
M Campos, H P Hughes, +3 authors, L A Babiuk.
Can J Vet Res, 1992 Jan 01; 56(1). PMID: 1586889    Free PMC article.
Pentoxifylline inhibits interleukin-2-induced toxicity in C57BL/6 mice but preserves antitumor efficacy.
M J Edwards, B T Heniford, +2 authors, F N Miller.
J Clin Invest, 1992 Aug 01; 90(2). PMID: 1644928    Free PMC article.
Interleukins. Clinical pharmacokinetics and practical implications.
V Bocci.
Clin Pharmacokinet, 1991 Oct 01; 21(4). PMID: 1760900
Immunopathological features of human pulmonary tumors following low-dose interleukin-2.
S G Swisher, T M Anderson, +4 authors, E C Holmes.
Cancer Immunol Immunother, 1991 Jan 01; 33(5). PMID: 1868491
Lymphokine-activated killer (LAK) cells modulate the effects of IL-2 on a T cell-mediated immune response.
P McCulloch, G Gallagher, +2 authors, J Xie.
Clin Exp Immunol, 1991 Sep 01; 85(3). PMID: 1893635    Free PMC article.
IL-4 acts as a homeostatic regulator of IL-2-induced TNF and IFN-gamma.
C Bello-Fernandez, P Oblakowski, +4 authors, M K Brenner.
Immunology, 1991 Feb 01; 72(2). PMID: 1901829    Free PMC article.
Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of children with dengue.
I Kurane, B L Innis, +4 authors, F A Ennis.
J Clin Invest, 1991 Nov 01; 88(5). PMID: 1939640    Free PMC article.
Highly Cited.
Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: II. Characterization of cells cultured ex vivo and their contribution to the in vivo immunomodulation.
C Fortis, E Ferrero, +5 authors, C Rugarli.
Cancer Immunol Immunother, 1991 Jan 01; 33(2). PMID: 2036660
Enhancement of a delayed hypersensitivity reaction to a contact allergen, by the systemic administration of interleukin-2.
Y Zaloom, L P Walsh, P McCulloch, G Gallagher.
Immunology, 1991 Apr 01; 72(4). PMID: 2037319    Free PMC article.
Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapy.
K Itoh, K Hayakawa, +7 authors, A A Zukiwski.
Cancer Immunol Immunother, 1991 Jan 01; 33(4). PMID: 2059968
An assessment of the effects of swainsonine on survival of mice injected with B16-F10 melanoma cells.
M J Humphries, K Matsumoto, +2 authors, K Olden.
Clin Exp Metastasis, 1990 Jan 01; 8(1). PMID: 2104578
The effect of recombinant interleukin 2 in combination with mitomycin C on advanced cancer.
T Akiyoshi, S Arinaga, +7 authors, H Matsuoka.
Jpn J Surg, 1990 May 01; 20(3). PMID: 2113592
Transcatheter arterial injection of autologous lymphokine-activated killer (LAK) cells into patients with liver cancers.
T Komatsu, K Yamauchi, T Furukawa, H Obata.
J Clin Immunol, 1990 May 01; 10(3). PMID: 2164039
Endogenous substances as drugs. Issues related to the application of cytokines in cancer therapy.
D R Parkinson.
Drug Saf, 1990 Jan 01; 5 Suppl 1. PMID: 2182067
Pharmacokinetics of repeated i.v. bolus administration of high doses of r-met-Hu interleukin-2 in advanced cancer patients.
J P Sculier, J J Body, +4 authors, M Paesmans.
Cancer Chemother Pharmacol, 1990 Jan 01; 26(5). PMID: 2208578
Tumor infiltrating lymphocytes.
A T Davidson.
J Natl Med Assoc, 1990 Sep 01; 82(9). PMID: 2213908    Free PMC article.
Involvement of thromboxane and neutrophils in multiple-system organ edema with interleukin-2.
R Welbourn, G Goldman, +3 authors, H B Hechtman.
Ann Surg, 1990 Dec 01; 212(6). PMID: 2256765    Free PMC article.
Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: I. Phenotypic and functional analysis of the peripheral blood mononuclear cells.
C Fortis, E Ferrero, +6 authors, C Rugarli.
Cancer Immunol Immunother, 1990 Jan 01; 32(3). PMID: 2289209
Addition of interleukin-2 in vitro augments detection of lymphokine-activated killer activity generated in vivo.
J A Hank, G Weil-Hillman, +2 authors, P M Sondel.
Cancer Immunol Immunother, 1990 Jan 01; 31(1). PMID: 2306756
Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells.
G B Mills, C May, +3 authors, A Marks.
J Clin Invest, 1990 Sep 01; 86(3). PMID: 2394835    Free PMC article.
Adoptive immunotherapy with interleukin-2 (IL-2) results in diminished IL-2 production by stimulated peripheral blood lymphocytes.
R Kradin, J Kurnick, +3 authors, D Lazarus.
J Clin Immunol, 1989 Sep 01; 9(5). PMID: 2533598
Evaluation of the effect of continuous infusion recombinant interleukin-2 (bioleukin) on peripheral blood leucocytes of patients with terminal malignancy.
R T Oliver, D Crosby, +2 authors, A Galazka.
Br J Cancer, 1989 Dec 01; 60(6). PMID: 2605101    Free PMC article.
Evaluation of natural killer and lymphokine-activated killer (LAK) cell activity in vivo in patients treated with high-dose interleukin-2 and adoptive transfer of autologous LAK cells.
J Walewski, E Paietta, J Dutcher, P H Wiernik.
J Cancer Res Clin Oncol, 1989 Jan 01; 115(2). PMID: 2654134
Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.
S A Rosenberg, M T Lotze, +4 authors, D E White.
Ann Surg, 1989 Oct 01; 210(4). PMID: 2679456    Free PMC article.
Highly Cited.
The clinical immunobiology of interleukin-2: potential modified uses for improved cancer treatment.
S D Voss, G Weil-Hillman, +2 authors, P M Sondel.
Bull N Y Acad Med, 1989 Jan 01; 65(1). PMID: 2690996    Free PMC article.
Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia.
D J Peace, M A Cheever.
J Exp Med, 1989 Jan 01; 169(1). PMID: 2783332    Free PMC article.
Influence of the donors' clinical status on in vitro and in vivo tumor-cytotoxic activation of interleukin-2-exposed lymphocytes and their circulation in different organs.
M Rodolfo, C Salvi, G Parmiani.
Cancer Immunol Immunother, 1989 Jan 01; 28(2). PMID: 2783888
A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma.
A Lindemann, K Höffken, +7 authors, J E Kolitz.
Cancer Immunol Immunother, 1989 Jan 01; 28(4). PMID: 2784715
Relative strength of the mitogenic and interleukin-2-production-inducing activities of staphylococcal exotoxins presumed to be causative exotoxins of toxic shock syndrome: toxic shock syndrome toxin-1 and enterotoxins A, B and C to murine and human T cells.
T Uchiyama, Y Kamagata, +4 authors, M Okubo.
Clin Exp Immunol, 1989 Feb 01; 75(2). PMID: 2784735    Free PMC article.
Severe intrahepatic cholestasis in patients treated with recombinant interleukin-2 and lymphokine-activated killer cells.
M Hoffman, A Mittelman, +6 authors, E Podack.
J Cancer Res Clin Oncol, 1989 Jan 01; 115(2). PMID: 2785519
Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation.
S D Voss, J A Hank, +3 authors, P M Sondel.
Cancer Immunol Immunother, 1989 Jan 01; 29(4). PMID: 2787694
In vivo biology of recombinant interleukin-2 infusion in sheep: cardiopulmonary manifestations of an intravascular immune-inflammatory response.
G J Jesmok, R A Gunther.
Inflammation, 1989 Jun 01; 13(3). PMID: 2787783
Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity.
D L Fraker, H N Langstein, J A Norton.
J Exp Med, 1989 Sep 01; 170(3). PMID: 2788701    Free PMC article.
Immunotherapy of hepatocellular carcinoma with autologous lymphokine-activated killer cells and/or recombinant interleukin-2.
T Ishikawa, M Imawari, +4 authors, F Takaku.
J Cancer Res Clin Oncol, 1988 Jan 01; 114(3). PMID: 2838488
Immunologic effects on peripheral lymphoid cells from patients with chronic hepatitis type B during administration of recombinant interleukin 2.
S Yamaguchi, M Onji, +2 authors, Y Ohta.
Clin Exp Immunol, 1988 Oct 01; 74(1). PMID: 2975535    Free PMC article.
Lysis of primary hepatic tumours by lymphokine activated killer cells.
K H Hsieh, S Y Shu, +3 authors, K J Chang.
Gut, 1987 Feb 01; 28(2). PMID: 3030899    Free PMC article.
The development of new immunotherapies for the treatment of cancer using interleukin-2. A review.
S A Rosenberg.
Ann Surg, 1988 Aug 01; 208(2). PMID: 3041925    Free PMC article.
The clinical potential of interleukin-2.
R T Oliver.
Br J Cancer, 1988 Oct 01; 58(4). PMID: 3061438    Free PMC article.
Three schedules of recombinant human interleukin-2 in the treatment of malignancy: side effects and immunologic effects in relation to serum level.
T Sano, N Saijo, +7 authors, K Nakagawa.
Jpn J Cancer Res, 1988 Jan 01; 79(1). PMID: 3128501    Free PMC article.
Interleukin 2 activity in peripheral blood mononuclear cells of patients with gynecologic malignancies.
Y Kikuchi, T Kita, +3 authors, I Kizawa.
Med Oncol Tumor Pharmacother, 1988 Jan 01; 5(2). PMID: 3137397
A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma.
P B Chapman, J E Kolitz, +7 authors, R Mertelsmann.
Invest New Drugs, 1988 Sep 01; 6(3). PMID: 3263958
Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients.
J W Mier, G Vachino, +7 authors, C A Dinarello.
J Clin Immunol, 1988 Nov 01; 8(6). PMID: 3265420
Administration in vivo of recombinant interleukin 2 protects mice against septic death.
C Weyand, J Goronzy, C G Fathman, P O'Hanley.
J Clin Invest, 1987 Jun 01; 79(6). PMID: 3294901    Free PMC article.
Modulation of cellular immune responses in mice with disseminated histoplasmosis by recombinant interleukin-2.
G S Deepe, C L Taylor, J E Harris, W E Bullock.
Infect Immun, 1986 Jul 01; 53(1). PMID: 3487507    Free PMC article.
The development of anti-interleukin-2 antibodies in patients treated with recombinant human interleukin-2 (IL-2).
M Allegretta, M B Atkins, +5 authors, J W Mier.
J Clin Immunol, 1986 Nov 01; 6(6). PMID: 3491089
Recruitment of inflammatory cells to a tumor deposit potentiates the immunotherapeutic effects of interleukin-2.
E P Steller, A M Eggermont, W Matthews, P H Sugarbaker.
Cancer Immunol Immunother, 1986 Jan 01; 23(3). PMID: 3491680
The anti-tumour efficacy of human recombinant interleukin 2. Correlation between sensitivity of tumours to the cytolytic effect of LAK cells in vitro and their susceptibility to interleukin 2 immunotherapy in vivo.
J Bubeník, M Indrová.
Cancer Immunol Immunother, 1987 Jan 01; 24(3). PMID: 3496154
Study of the biological activities of toxic shock syndrome toxin-1: II. Induction of the proliferative response and the interleukin 2 production by T cells from human peripheral blood mononuclear cells stimulated with the toxin.
T Uchiyama, Y Kamagata, +7 authors, T Saito-Taki.
Clin Exp Immunol, 1987 Jun 01; 68(3). PMID: 3498581    Free PMC article.
The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T-cell infiltration and HLA-DR expression.
P J Cohen, M T Lotze, +2 authors, E S Jaffe.
Am J Pathol, 1987 Nov 01; 129(2). PMID: 3499823    Free PMC article.
The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
S E Ettinghausen, S A Rosenberg.
Springer Semin Immunopathol, 1986 Jan 01; 9(1). PMID: 3523804
Immunotherapy for cancer: the use of lymphokine activated killer (LAK) cells.
E A Fagan, A L Eddleston.
Gut, 1987 Feb 01; 28(2). PMID: 3549471    Free PMC article.
Transgenic mice in the study of cytokine function.
J Taverne.
Int J Exp Pathol, 1993 Dec 01; 74(6). PMID: 7507352    Free PMC article.
Interleukins. Clinical pharmacology and therapeutic use.
W E Aulitzky, M Schuler, C Peschel, C Huber.
Drugs, 1994 Nov 01; 48(5). PMID: 7530625
Cytokine and lymphocyte activation during experimental acute pyelonephritis.
J A Roberts, M B Kaack, L N Martin.
Urol Res, 1995 Jan 01; 23(1). PMID: 7618233
Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.
M A Caligiuri, C Murray, +7 authors, R J Soiffer.
J Clin Invest, 1993 Jan 01; 91(1). PMID: 7678599    Free PMC article.
Induction of tumor-specific cytotoxic T lymphocytes and natural killer cells by tumor cells transfected with the interleukin-2 gene.
Y Iwanuma, K Kato, H Yagita, K Okumura.
Cancer Immunol Immunother, 1995 Jan 01; 40(1). PMID: 7828164
Effects of route and formulation on clinical pharmacokinetics of interleukin-2.
P M Anderson, M A Sorenson.
Clin Pharmacokinet, 1994 Jul 01; 27(1). PMID: 7955769
Effect of interleukin-2 on the biodistribution of technetium-99m-labelled anti-CEA monoclonal antibody in mice bearing human tumour xenografts.
K Nakamura, A Kubo.
Eur J Nucl Med, 1994 Sep 01; 21(9). PMID: 7995285
Cytokines as mediators in the regulation of the hypothalamic-pituitary-adrenocortical function.
J Fukata, H Imura, K Nakao.
J Endocrinol Invest, 1994 Feb 01; 17(2). PMID: 8006336
The intrapleural administration of recombinant interleukin-2 (rIL-2) to patients with malignant pleural effusion: clinical trials.
H Suzuki, S Abo, +2 authors, K Izumi.
Surg Today, 1993 Jan 01; 23(12). PMID: 8118118
Generation of tumor-specific cytotoxic T lymphocytes in vivo by combined treatment with inactivated tumor cells and recombinant interleukin-2.
M Harada, G Matsuzaki, +7 authors, K Nomoto.
Cancer Immunol Immunother, 1994 May 01; 38(5). PMID: 8162615
Opposite effects of interleukin-2 on normal and transfusion-suppressed healing of experimental intestinal anastomoses.
T Tadros, T Wobbes, T Hendriks.
Ann Surg, 1993 Dec 01; 218(6). PMID: 8257231    Free PMC article.
A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects.
L T Vlasveld, A Hekman, +7 authors, C J Melief.
Br J Cancer, 1993 Sep 01; 68(3). PMID: 8353046    Free PMC article.
Clinical aspects of the melatonin action: impact of development, aging, and puberty, involvement of melatonin in psychiatric disease and importance of neuroimmunoendocrine interactions.
F Waldhauser, B Ehrhart, E Förster.
Experientia, 1993 Aug 15; 49(8). PMID: 8359273
Influence of LAK cells on expression of HLA-DR antigen on laryngeal carcinoma cell line in new culture systems.
H Kumazawa, T Kumazawa, +3 authors, K Kawamoto.
Eur Arch Otorhinolaryngol, 1993 Jan 01; 250(4). PMID: 8369118
Immunotherapy with intralesional and systemic interleukin-2 of patients with non-small-cell lung cancer.
M Scudeletti, G Filaci, +6 authors, F Puppo.
Cancer Immunol Immunother, 1993 Jul 01; 37(2). PMID: 8391391
Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: a phase-IB study.
A Lindemann, P Brossart, +6 authors, R Mertelsmann.
Cancer Immunol Immunother, 1993 Oct 01; 37(5). PMID: 8402734
Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.
J W Gratama, R J Bruin, +4 authors, R L Bolhuis.
Clin Exp Immunol, 1993 May 01; 92(2). PMID: 8485906    Free PMC article.
Systemic immunological effects of cytokine genes injected into skeletal muscle.
E Raz, A Watanabe, +5 authors, D A Carson.
Proc Natl Acad Sci U S A, 1993 May 15; 90(10). PMID: 8506293    Free PMC article.
Locoregional therapy with polyethylene-glycol-modified interleukin-2 of an intradermally growing hepatocellular carcinoma in the guinea pig induces T-cell-mediated antitumor activity.
L T Balemans, V Mattijssen, +3 authors, W Den Otter.
Cancer Immunol Immunother, 1993 Jul 01; 37(1). PMID: 8513455
High-dose continuous venous infusion of interleukin-2: influence of dose and infusion rate on tumoricidal function and lymphocyte subsets.
W C Mertens, D Banerjee, +3 authors, P K Lala.
Cancer Immunol Immunother, 1995 Nov 01; 41(5). PMID: 8536272
Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity.
E L Jacobson, F Pilaro, K A Smith.
Proc Natl Acad Sci U S A, 1996 Sep 17; 93(19). PMID: 8816813    Free PMC article.
Treatment of metastatic renal cell carcinoma with subcutaneous interleukin 2: evidence for non-renal clearance of cytokines.
R E Banks, M A Forbes, +10 authors, P J Selby.
Br J Cancer, 1997 Jan 01; 75(12). PMID: 9192992    Free PMC article.
Postoperative enteritis caused by methicillin-resistant Staphylococcus aureus.
T Kodama, T Santo, +8 authors, Y Matsuura.
Surg Today, 1997 Jan 01; 27(9). PMID: 9306604
Intralymphatic interleukin-2 in combination with zidovudine for the therapy of patients with AIDS.
T Harrer, J Schwab, +6 authors, M Gramatzki.
Infection, 1998 Dec 23; 26(6). PMID: 9861562
Effects of immunization with tumor cells double transfected with interleukin-2 (IL-2) and interleukin-12 (IL-12) genes on artificial metastasis of colon26 cells in BALB/c mice.
T Takada, K Kato, +2 authors, K Okumura.
Clin Exp Metastasis, 1999 Jul 20; 17(2). PMID: 10411104
Cancer vaccine development: protein transfer of membrane-anchored cytokines and immunostimulatory molecules.
Ashley M Cimino, Purani Palaniswami, Andrew C Kim, Periasamy Selvaraj.
Immunol Res, 2004 Jun 08; 29(1-3). PMID: 15181285
Taurine attenuates CD3/interleukin-2-induced T cell apoptosis in an in vitro model of activation-induced cell death (AICD).
S G Maher, C E M Condron, D J Bouchier-Hayes, D M Toomey.
Clin Exp Immunol, 2005 Jan 19; 139(2). PMID: 15654826    Free PMC article.
Homing of radiolabelled recombinant interleukin-2 activated natural killer cells and their efficacy in adoptive immunotherapy against murine fibrosarcoma.
Anuradha Rai, Ashim K Chakravarty.
J Biosci, 2008 Jan 19; 32(7). PMID: 18202454
Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2.
Bianca Heemskerk, Ke Liu, +9 authors, Steven A Rosenberg.
Hum Gene Ther, 2008 May 01; 19(5). PMID: 18444786    Free PMC article.
Suppression of murine allergic airway disease by IL-2:anti-IL-2 monoclonal antibody-induced regulatory T cells.
Mark S Wilson, John T Pesce, +3 authors, Thomas A Wynn.
J Immunol, 2008 Nov 05; 181(10). PMID: 18981114    Free PMC article.
Safety and immunologic effects of IL-15 administration in nonhuman primates.
Carolina Berger, Michael Berger, +4 authors, Stanley R Riddell.
Blood, 2009 Jul 17; 114(12). PMID: 19605850    Free PMC article.
Highly Cited.
Interleukin-2 is present in human blood vessels and released in biologically active form by heparanase.
John D Miller, Suzanne E Clabaugh, +2 authors, Lucile E Wrenshall.
Immunol Cell Biol, 2011 May 25; 90(2). PMID: 21606942    Free PMC article.
IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I/II study.
Claudia Brehm, Sabine Huenecke, +13 authors, Ulrike Koehl.
PLoS One, 2011 Nov 19; 6(11). PMID: 22096557    Free PMC article.
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
James N Kochenderfer, Mark E Dudley, +15 authors, Steven A Rosenberg.
Blood, 2011 Dec 14; 119(12). PMID: 22160384    Free PMC article.
Highly Cited.
Comparison of interferon-γ-, interleukin (IL)-17- and IL-22-expressing CD4 T cells, IL-22-expressing granulocytes and proinflammatory cytokines during latent and active tuberculosis infection.
J Cowan, S Pandey, +3 authors, D W Cameron.
Clin Exp Immunol, 2012 Jan 13; 167(2). PMID: 22236009    Free PMC article.
IL-2 induces the release of secondary cytokines which stimulate the cytotoxic activity of either NK or CD8(+) lymphocytes.
U Testa, D Bulgarini, +5 authors, C Peschle.
Cytotechnology, 1991 Feb 01; 5(Suppl 1). PMID: 22358974
Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma.
Serena K Perna, Biagio De Angelis, +8 authors, Barbara Savoldo.
Clin Cancer Res, 2012 Nov 15; 19(1). PMID: 23149818    Free PMC article.
Oligodeoxynucleotides expressing polyguanosine motifs promote antitumor activity through the upregulation of IL-2.
Nobuaki Kobayashi, Choongman Hong, Dennis M Klinman, Hidekazu Shirota.
J Immunol, 2013 Jan 09; 190(4). PMID: 23296706    Free PMC article.
Expression of membrane anchored cytokines and B7-1 alters tumor microenvironment and induces protective antitumor immunity in a murine breast cancer model.
Erica N Bozeman, Ashley Cimino-Mathews, +5 authors, Periasamy Selvaraj.
Vaccine, 2013 Apr 02; 31(20). PMID: 23541884    Free PMC article.
Baseline tumor growth and immune control in laboratory mice are significantly influenced by subthermoneutral housing temperature.
Kathleen M Kokolus, Maegan L Capitano, +8 authors, Elizabeth A Repasky.
Proc Natl Acad Sci U S A, 2013 Nov 20; 110(50). PMID: 24248371    Free PMC article.
Highly Cited.
Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy.
Denise Skrombolas, John G Frelinger.
Expert Rev Clin Immunol, 2014 Jan 15; 10(2). PMID: 24410537    Free PMC article.
IL-2: the first effective immunotherapy for human cancer.
Steven A Rosenberg.
J Immunol, 2014 Jun 08; 192(12). PMID: 24907378    Free PMC article.
Highly Cited. Review.
Agents that increase AAM differentiation blunt RSV-mediated lung pathology.
Kari Ann Shirey, Wendy Lai, +4 authors, Stefanie N Vogel.
J Leukoc Biol, 2014 Jul 11; 96(6). PMID: 25009233    Free PMC article.
Neutrophil:lymphocyte ratios and serum cytokine changes after hepatic artery chimeric antigen receptor-modified T-cell infusions for liver metastases.
A Saied, L Licata, +9 authors, S C Katz.
Cancer Gene Ther, 2014 Oct 04; 21(11). PMID: 25277132    Free PMC article.
Targeting CD8+ T-cell tolerance for cancer immunotherapy.
Stephanie R Jackson, Jinyun Yuan, Ryan M Teague.
Immunotherapy, 2014 Oct 08; 6(7). PMID: 25290416    Free PMC article.
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.
Dalil Hannani, Marie Vétizou, +30 authors, Laurence Zitvogel.
Cell Res, 2015 Jan 15; 25(2). PMID: 25582080    Free PMC article.
Highly Cited.
Inhibition of G-protein βγ signaling enhances T cell receptor-stimulated interleukin 2 transcription in CD4+ T helper cells.
Evan A Yost, Thomas R Hynes, +2 authors, Catherine H Berlot.
PLoS One, 2015 Jan 30; 10(1). PMID: 25629163    Free PMC article.
Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases.
Steven C Katz, Rachel A Burga, +11 authors, Richard P Junghans.
Clin Cancer Res, 2015 Apr 09; 21(14). PMID: 25850950    Free PMC article.
Highly Cited.
Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells.
Rodrigo Vazquez-Lombardi, Claudia Loetsch, +8 authors, Daniel Christ.
Nat Commun, 2017 May 13; 8. PMID: 28497796    Free PMC article.
High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute.
Diwakar Davar, Fei Ding, +4 authors, Hussein A Tawbi.
J Immunother Cancer, 2017 Sep 20; 5(1). PMID: 28923120    Free PMC article.
Tamm-Horsfall Protein is a Potent Immunomodulatory Molecule and a Disease Biomarker in the Urinary System.
Tsai-Hung Wu, Ko-Jen Li, Chia-Li Yu, Chang-Youh Tsai.
Molecules, 2018 Jan 25; 23(1). PMID: 29361765    Free PMC article.
IL-2 and Beyond in Cancer Immunotherapy.
John M Wrangle, Alicia Patterson, +7 authors, Mark P Rubinstein.
J Interferon Cytokine Res, 2018 Feb 15; 38(2). PMID: 29443657    Free PMC article.
A Dose-escalation Study of Recombinant Human Interleukin-18 in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma.
Michael J Robertson, Christopher W Stamatkin, +3 authors, Ahmad R Safa.
J Immunother, 2018 Mar 09; 41(3). PMID: 29517616    Free PMC article.
In vivo neutralization of the protagonist role of macrophages during the chronic inflammatory stage of Huntington's disease.
Jeffrey Pido-Lopez, Ralph Andre, +4 authors, Gillian P Bates.
Sci Rep, 2018 Aug 01; 8(1). PMID: 30061661    Free PMC article.
Engineering a Single-Agent Cytokine/Antibody Fusion That Selectively Expands Regulatory T Cells for Autoimmune Disease Therapy.
Jamie B Spangler, Eleonora Trotta, +10 authors, K Christopher Garcia.
J Immunol, 2018 Aug 15; 201(7). PMID: 30104245    Free PMC article.
Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2.
Zuqiang Liu, Yan Ge, +5 authors, David L Bartlett.
Nat Commun, 2018 Nov 10; 9(1). PMID: 30410056    Free PMC article.
Interleukin 2 is an Upstream Regulator of CD4+ T Cells From Visceral Leishmaniasis Patients With Therapeutic Potential.
Shashi Bhushan Chauhan, Rebecca Faleiro, +12 authors, Christian Engwerda.
J Infect Dis, 2019 Feb 24; 220(1). PMID: 30796820    Free PMC article.
NK Cell-Based Immunotherapy for Hematological Malignancies.
Simona Sivori, Raffaella Meazza, +6 authors, Daniela Pende.
J Clin Med, 2019 Oct 19; 8(10). PMID: 31623224    Free PMC article.
Albumin-based cancer therapeutics for intraperitoneal drug delivery: a review.
Leen Van de Sande, Sarah Cosyns, Wouter Willaert, Wim Ceelen.
Drug Deliv, 2019 Dec 21; 27(1). PMID: 31858848    Free PMC article.
Exploiting Human NK Cells in Tumor Therapy.
Paola Vacca, Gabriella Pietra, +3 authors, Lorenzo Moretta.
Front Immunol, 2020 Feb 06; 10. PMID: 32010130    Free PMC article.
NK Cell-Based Immune Checkpoint Inhibition.
Muhammad Khan, Sumbal Arooj, Hua Wang.
Front Immunol, 2020 Mar 03; 11. PMID: 32117298    Free PMC article.
T cell immunotherapy enhanced by designer biomaterials.
Zachary S Dunn, John Mac, Pin Wang.
Biomaterials, 2019 Jul 05; 217. PMID: 31271861    Free PMC article.
Anticancer Drug-induced Thyroid Dysfunction.
Saptarshi Bhattacharya, Alpesh Goyal, +2 authors, Sanjay Kalra.
Eur Endocrinol, 2020 Jul 01; 16(1). PMID: 32595767    Free PMC article.
Harnessing NK Cell Checkpoint-Modulating Immunotherapies.
Sachin Kumar Singh Chauhan, Ulrike Koehl, Stephan Kloess.
Cancers (Basel), 2020 Jul 10; 12(7). PMID: 32640575    Free PMC article.
Mature Dendritic Cells May Promote High-Avidity Tuning of Vaccine T Cell Responses.
Adarsh Kumbhari, Colt A Egelston, Peter P Lee, Peter S Kim.
Front Immunol, 2020 Nov 17; 11. PMID: 33193401    Free PMC article.
Prevention of interleukin-2 withdrawal-induced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor T-cell receptor and an antiapoptotic protein.
Anusha Kalbasi, Rajeev K Shrimali, Dhanalakshmi Chinnasamy, Steven A Rosenberg.
J Immunother, 2010 Jul 29; 33(7). PMID: 20664359    Free PMC article.
De novo design of potent and selective mimics of IL-2 and IL-15.
Daniel-Adriano Silva, Shawn Yu, +22 authors, David Baker.
Nature, 2019 Jan 11; 565(7738). PMID: 30626941    Free PMC article.
Highly Cited.
Treg cell-based therapies: challenges and perspectives.
Caroline Raffin, Linda T Vo, Jeffrey A Bluestone.
Nat Rev Immunol, 2019 Dec 08; 20(3). PMID: 31811270    Free PMC article.
Harnessing cancer immunotherapy during the unexploited immediate perioperative period.
Pini Matzner, Elad Sandbank, +3 authors, Shamgar Ben-Eliyahu.
Nat Rev Clin Oncol, 2020 Feb 19; 17(5). PMID: 32066936
The evolution of commercial drug delivery technologies.
Ava M Vargason, Aaron C Anselmo, Samir Mitragotri.
Nat Biomed Eng, 2021 Apr 03; 5(9). PMID: 33795852
Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy.
Philipp Wendel, Lisa Marie Reindl, +7 authors, Evelyn Ullrich.
Cancers (Basel), 2021 Apr 04; 13(6). PMID: 33807011    Free PMC article.
A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy.
Eric J Hsu, Xuezhi Cao, +4 authors, Yang-Xin Fu.
Nat Commun, 2021 May 15; 12(1). PMID: 33986267    Free PMC article.
A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cells.
Katherine E Harris, Kyle J Lorentsen, +18 authors, Nathan D Trinklein.
Sci Rep, 2021 May 21; 11(1). PMID: 34011961    Free PMC article.
Regulatory T Cell Therapy of Graft-versus-Host Disease: Advances and Challenges.
Mehrdad Hefazi, Sara Bolivar-Wagers, Bruce R Blazar.
Int J Mol Sci, 2021 Sep 29; 22(18). PMID: 34575843    Free PMC article.
Engineering Strategies for Immunomodulatory Cytokine Therapies - Challenges and Clinical Progress.
Ivan S Pires, Paula T Hammond, Darrell J Irvine.
Adv Ther (Weinh), 2021 Nov 05; 4(8). PMID: 34734110    Free PMC article.
Site-specific PEGylation of interleukin-2 enhances immunosuppression via the sustained activation of regulatory T cells.
Bo Zhang, Jiaqi Sun, +22 authors, Xuan Zhang.
Nat Biomed Eng, 2021 Sep 29; 5(11). PMID: 34580438
MK-6, a novel not-α IL-2, elicits a potent antitumor activity by improving the effector to regulatory T cell balance.
Maki Kobayashi, Katsuhiko Kojima, +6 authors, Nobuyuki Tanaka.
Cancer Sci, 2021 Sep 22; 112(11). PMID: 34545658    Free PMC article.
Engineering IL-2 for immunotherapy of autoimmunity and cancer.
Rosmely Hernandez, Janika Põder, Kathryn M LaPorte, Thomas R Malek.
Nat Rev Immunol, 2022 Feb 27;. PMID: 35217787
Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus.
Christie Fanton, Richard Furie, +9 authors, Brian L Kotzin.
J Transl Autoimmun, 2022 May 07; 5. PMID: 35517914    Free PMC article.